Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$17.46 USD

17.46
5,699,855

-0.21 (-1.19%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $17.41 -0.05 (-0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 15% (39 out of 252)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA

The FDA accepts Alkermes (ALKS) and partner Biogen's NDA for diroximel fumarate and sets an action date in the fourth quarter of 2019.

Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat

Momenta (MNTA) reported a narrower loss in Q4, while sales came ahead of expectations.

Mylan (MYL) to Report Q4 Earnings: What's in the Offing?

Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.

Allergan Responds to Investor's Call for CEO/Chair Role Split

Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.

Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study

Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.

What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.

Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down

Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.

Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report

Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.

Earnings & Data Deluge

Earnings & Data Deluge

Mark Vickery headshot

Markets Keeping Optimistic... For Now; Plus HLT, TEVA, DISH

Pre-market futures are again trading up today, as expectations continue to be favorable for two things that have yet to be officially resolved.

Teva (TEVA) Misses on Q4 Earnings, Beats Sales, Shares Down

Teva's (TEVA) fourth-quarter earnings misses estimates but sales beat expectations. Teva???s sales and earnings guidance for 2019 is weaker than expected.

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $18.22, marking a -0.71% move from the previous day.

Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down

Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.

Why the Earnings Surprise Streak Could Continue for Teva Pharmaceutical Industries Ltd. (TEVA)

Teva Pharmaceutical Industries Ltd. (TEVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy

Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $19.70, moving -0.76% from the previous trading session.

J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study

Johnson & Johnson's (JNJ) Erleada improves survival in metastatic castration-sensitive prostate cancer study.

Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study

Eli Lilly (LLY) and Pfizer announce that their investigational pain candidate, tanezumab, achieves significant reduction in pain in osteoarthritis patients in second late-stage study.

Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid

Amgen (AMGN) beats estimates for both earnings and sales in Q4. Its forecast for 2019 disappoints investors Stock dips 2.4% in after-hours trading.

AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting

AbbVie's (ABBV) key cancer drug, Imbruvica, in combination with Gazyva, gets FDA approval for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in first-line setting.

Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results

Allergan (AGN) approves a cash dividend of 74 cents for 2019, a 2.8% raise from the previous payout of 72 cents.

Merck's Partner Gets FDA Nod for Herceptin Biosimilar

Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.

Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $18.76, moving +0.59% from the previous trading session.

6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019

Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.